Key Points
- BeOne Medicines SVP Chan Henry Lee sold 332 shares on May 13 at an average price of $310.72, for total proceeds of about $103,159. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Lee held 101 shares valued at roughly $31,383, representing a 76.67% reduction in his position. He had also sold 332 shares in April and 341 shares in March.
- ONC shares were down 3.7% and opened at $293.27, while analysts remain generally positive with a consensus rating of Moderate Buy and an average price target of $389.15.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 332 shares of the business's stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $310.72, for a total transaction of $103,159.04. Following the completion of the transaction, the senior vice president owned 101 shares in the company, valued at $31,382.72. This represents a 76.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Chan Henry Lee also recently made the following trade(s):
- On Wednesday, April 8th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $311.59, for a total value of $103,447.88.
- On Wednesday, March 11th, Chan Henry Lee sold 341 shares of BeOne Medicines stock. The stock was sold at an average price of $300.00, for a total value of $102,300.00.
BeOne Medicines Trading Down 3.7%
NASDAQ:ONC opened at $293.27 on Friday. The stock has a market cap of $32.18 billion, a price-to-earnings ratio of 65.61 and a beta of 0.50. BeOne Medicines Ltd. - Sponsored ADR has a one year low of $227.05 and a one year high of $385.22. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The business's 50-day simple moving average is $300.41 and its 200 day simple moving average is $321.73.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion during the quarter. As a group, sell-side analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post 5.3 earnings per share for the current fiscal year.
Institutional Investors Weigh In On BeOne Medicines
A number of hedge funds have recently made changes to their positions in ONC. EFG International AG acquired a new position in shares of BeOne Medicines during the fourth quarter worth approximately $25,000. Leonteq Securities AG bought a new stake in BeOne Medicines during the 4th quarter valued at $35,000. Daiwa Securities Group Inc. bought a new stake in BeOne Medicines during the 2nd quarter valued at $35,000. CWM LLC boosted its position in BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company's stock worth $48,000 after acquiring an additional 39 shares during the period. Finally, Group One Trading LLC bought a new position in shares of BeOne Medicines in the fourth quarter worth $61,000. Institutional investors own 48.55% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on ONC. Morgan Stanley restated an "overweight" rating and issued a $395.00 price target on shares of BeOne Medicines in a research note on Thursday, May 7th. Barclays raised their price objective on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an "overweight" rating in a report on Thursday, May 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of BeOne Medicines in a research report on Monday, April 20th. Wolfe Research started coverage on shares of BeOne Medicines in a research report on Friday, March 27th. They set an "outperform" rating and a $340.00 price target on the stock. Finally, Wells Fargo & Company assumed coverage on BeOne Medicines in a research note on Monday, May 4th. They issued an "overweight" rating and a $400.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $389.15.
View Our Latest Analysis on ONC
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
